Abemaciclib plus endocrine therapy versus chemotherapy after progression on prior palbociclib in HR+/HER2- metastatic breast cancer: A single center real-world study in China.

Hanfang JiangJianxin ZhongJing WangGuohong SongLijun DiBin ShaoRuyan ZhangYaxin LiuAnjie ZhuNan WangHuiping Li

Published in: Cancer medicine (2024)

Our findings indicate that abemaciclib plus switching ET might be one of feasible treatment options for Chinese patients with HR+/HER2- MBC after progression on prior palbociclib-based therapy in addition to chemotherapy.

Keyphrases

metastatic breast cancer
locally advanced
squamous cell carcinoma
rectal cancer
bone marrow
chemotherapy induced